91790-91-9

Usage

Uses

Used in Pharmaceutical Industry:
(S)-4-(2-Pyrrolidinylmethyl)morpholine is used as a chiral auxiliary for the synthesis of biologically active compounds, leveraging its unique stereochemistry to influence the outcome of chemical reactions and produce enantiomerically pure products, which is crucial for the development of effective and safe medications.
Used in Chemical Industry:
In the chemical industry, (S)-4-(2-Pyrrolidinylmethyl)morpholine serves as a building block for the synthesis of potential therapeutic agents, contributing to the creation of new molecules with specific biological activities that can be used for treating various diseases and conditions.
Used in Coordination Chemistry:
(S)-4-(2-Pyrrolidinylmethyl)morpholine is used as a ligand in coordination chemistry, where it can form complexes with metal ions. This application is significant for the study of metal-organic frameworks and the development of new materials with tailored properties for various applications, such as catalysis, sensing, and drug delivery.

Upstream product

• 110-91-8 morpholine 
• 132635-95-1 5-(S)-<3.3.0>-1-aza-2-thia-3-oxabicyclooctane-2,2-dioxide 
• 23356-96-9 (S)-1-Pyrrolidin-2-yl-methanol 
• 1148-11-4 N-Benzyloxycarbonyl-L-proline 
• 380236-96-4 (S)-2-morpholin-4-ylmethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 66165-42-2 (S)-4-morpholine 
• 52682-03-8 (S)(-)-N,O-bis(p-toluenesulphonyl)-2-hydroxymethyl pyrrolidine 
• 73094-26-5 morpholino(pyrrolidin-2-yl)methanone 
• 1013941-83-7 2-(R,S)-5-(S)-<3.3.0>-1-aza-2-thia-3-oxabicyclooctane-2-oxide 
• 114671-25-9 (S)-N-(p-toluenesulphonyl)-2-(morpholinomethyl) pyrrolidine 

Relevant academic research and scientific papers

NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS

The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. The invention novel betulinic substituted amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

Sulfonamide lactam inhibitors of FXa and method

Sulfonamide lactams of the following formula wherein X, R1, R2, R3, R4, R4a, R5, R5a, R6, R6a, R7 and R8 are as described herein, are provided which inhibitors of Factor Xa and are useful as anticoagulants in the treatment of cardiovascular diseases associated with thromboses.

Thiophene derivatives useful as anticancer agents

The invention relates to compounds of the formula 1 or a pharmaceutically acceptable salt and to pharmaceutically acceptable salts and hydrates thereof, wherein X, Y, R1, R2 and R11 are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating hyperproliferative disorders in a mammal by administering the compounds of formula 1.

The direct synthesis of the cyclic sulphamidate of (S)-prolinol: Simultaneous N-protection and activation towards nucleophilic displacement of oxygen

The preparation of the cyclic sulphamidate of (S)-prolinol has been achieved by reaction with sulphuryl chloride at low temperature. This material has been shown to be susceptible to acid catalysed nucleophilic attack to furnish 2-(N,N-dialkylamino)methyl- and 2-(methoxymethyl)pyrrolidines after hydrolysis of the intermediate sulphamic acid derivatives.

PREPARATION OF PROLINE DERIVED LITHIUM AMIDE BASES AND THEIR USE IN ENANTIOSELECTIVE DEPROTONATION OF MESO EPOXIDES

An alternative method of preparation for a range of proline derived chiral lithium amide bases is described. (S)-2-(Pyrrolidinomethyl) pyrrolidine, prepared by the new route, has been used to deprotonate cis and trans tbutyldimethylisiloxy-3,4-epoxycyclopentane enantioselectively, thus generating chiral cis and trans tbutyldimethylsiloxy-2-cyclopenten-4-ols.The products had higher enantiomeric purity than those produced when the base was prepared by a previously reported method.